The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

November 23, 2017

Study Completion Date

November 23, 2017

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

TNP-2092 capsules

TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.

DRUG

TNP-2092 capsules placebo

TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.

DRUG

Rabeprazole sodium enteric-coated tablets

Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

TenNor Therapeutics Inc.

INDUSTRY

NCT06337604 - The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets | Biotech Hunter | Biotech Hunter